Core Viewpoint - Polyrizon Ltd. has received a notification from Nasdaq regarding potential delisting due to shareholder dilution concerns related to a recent securities issuance [1][2] Group 1: Company Overview - Polyrizon is a development stage biotech company focused on innovative intranasal hydrogels that create a barrier against viruses and allergens in the nasal cavity [3] - The company's proprietary technology, Capture and Contain (C&C), is designed to function as a "biological mask" and is delivered via nasal sprays [3] - Polyrizon is also developing Trap and Target (T&T) technology for the nasal delivery of active pharmaceutical ingredients, which is currently in pre-clinical development [3] Group 2: Nasdaq Notification Details - Nasdaq's Listing Qualifications Department has determined that the issuance of Series A warrants under a securities purchase agreement raises public interest concerns due to substantial dilution for shareholders [1] - The company has the option to request a hearing before a Hearings Panel to contest the delisting, which would stay any suspension or delisting actions pending the outcome of the hearing [2]
Polyrizon Announces Receipt of Nasdaq Delisting Notice